Efficacy and safety of onabotulinumtoxinA in patients with neurogenic detrusor overactivity: A systematic review and meta-analysis of randomized controlled trials

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Cheng, Tao ^a   Shuang, Wei Bing ^a   Jia, Dong Dong ^b   Zhang, Min ^a   Tong, Xu Nan ^a   Yang, Wei Dong ^c   Jia, Xu Ming ^d   Li, Shuo ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

^c HEBEI UNIVERSITY   (China)

^d ShanXi Hospital of Integrated Traditional and Western Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

COMPLICATION; DOSE RESPONSE; FEMALE; HUMAN; MALE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); URINARY BLADDER, NEUROGENIC; URINARY INCONTINENCE; URODYNAMICS;

BOTULINUM TOXINS, TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINARY BLADDER, NEUROGENIC; URINARY INCONTINENCE; URODYNAMICS;

EID: 85016606507     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0159307     Document Type: Review

References (25)

1. Al Taweel W, Alzyoud KM. The effect of spinal cord-injury level on the outcome of neurogenic bladder treatment using OnabotulinumtoxinA. Urol Ann. 2015; 7: 320–324. doi: 10.4103/0974-7796.152013 PMID: 26229318
2. Seth JH, Dowson C, Khan MS, Panicker JN, Fowler CJ, Dasgupta P, et al. Botulinum toxin-A for the treatment of overactive bladder: UK contributions. J Clin Urol. 2013; 6: 77–83. PMID: 26097709
3. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002; 21: 167–178. PMID: 11857671
4. Lee JS, Koo BI, Shin MJ, Chang JH, Kim SY, Ko HY. Differences in urodynamic variables for vesicoureteral reflux depending on the neurogenic bladder type. Ann Rehabil Med. 2014; 38: 347–352. doi: 10. 5535/arm.2014.38.3.347 PMID: 25024958
5. Jundt K, Schreyer K, Friese K, Peschers U. Anticholinergic therapy: do the patients take the pills prescribed? Arch Gynecol Obstet. 2011; 284: 663–666. doi: 10.1007/s00404-010-1720-x PMID: 21046135
6. Smith CP, Boone TB, de Groat WC, Chancellor MB, Somogyi GT. Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull. 2003; 61: 165–171. PMID: 12832003
7. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000; 164: 692–697. PMID: 10953127
8. Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005; 174: 196–200. PMID: 15947626
9. Chancellor MB, Patel V, Leng WW, Shenot PJ, Lam W, Globe DR, et al. OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. Neurology. 2013; 81: 841–848. doi: 10. 1212/WNL.0b013e3182a2ca4d PMID: 23892704
10. Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011; 185: 2229–2235. doi: 10.1016/j.juro.2011.02.004 PMID: 21497851
11. Rovner E, Dmochowski R, Chapple C, Thompson C, Lam W, Haag-Molkenteller C. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2013; 32: 1109–1115. doi: 10.1002/nau.22376 PMID: 23389824
12. Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012; 187: 2131–2139. doi: 10.1016/j.juro.2012.01.125 PMID: 22503020
13. Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011; 60: 742–750. doi: 10.1016/j.eururo.2011.07.002 PMID: 21798658
14. Knuepfer S, Juenemann KP. Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice. Ther Adv Urol. 2014; 6: 34–42. doi: 10.1177/ 1756287213510962 PMID: 24489607
15. Kessler TM, Bachmann LM, Minder C, Lohrer D, Umbehr M, Schunemann HJ, et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One. 2011; 6: e16718. doi: 10.1371/journal.pone.0016718 PMID: 21373193
16. Reitz A, Stohrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 2004; 45: 510–515. PMID: 15041117
17. Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol. 2007; 41: 335–340. PMID: 17763227
18. Nuanthaisong U, Abraham N, Goldman HB. Incidence of adverse events after high doses of onabotulinumtoxinA for multiple indications. Urology. 2014; 84: 1044–1048. doi: 10.1016/j.urology.2014.07.046 PMID: 25443898
19. Gulamhusein A, Mangera A. OnabotulinumtoxinA in the treatment of neurogenic bladder. Biologics. 2012; 6: 299–306. doi: 10.2147/BTT.S30180 PMID: 22977301
20. Chuang YC, Kaufmann JH, Chancellor DD, Chancellor MB, Kuo HC. Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial. J Urol. 2014; 192: 1743–1749. doi: 10.1016/j.juro.2014.07.008 PMID: 25046622
21. Leitner L, Walter M, Freund P, Mehnert U, Michels L, Kollias S, et al. Protocol for a prospective magnetic resonance imaging study on supraspinal lower urinary tract control in healthy subjects and spinal cord injury patients undergoing intradetrusor onabotulinumtoxinA injections for treating neurogenic detrusor overactivity. BMC Urol. 2014; 14: 68. doi: 10.1186/1471-2490-14-68 PMID: 25132340
22. Chartier-Kastler E, Rovner E, Hepp Z, Khalaf K, Ni Q, Chancellor M. Patient-reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2015. doi: 10.1002/nau.22757
23. Chen SF, Kuo HC. Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity. J Formos Med Assoc. 2015; 114: 583–589. doi: 10.1016/j.jfma.2013.10.009 PMID: 24262922
24. Mangera A, Andersson KE, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol. 2011; 60: 784–795. doi: 10.1016/j.eururo. 2011.07.001 PMID: 21782318
25. Linsenmeyer TA. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. J Spinal Cord Med. 2013; 36: 402–419.25. doi: 10.1179/2045772313Y.0000000116 PMID: 23941788